About the Company

A.P. Pharma, Inc. (OTCBB:APPA.OB) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company’s primary focus is on its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV). A.P. Pharma received a Complete Response Letter on the APF530 NDA and is targeting the resubmission of the NDA for the first half of 2012. The Company has additional clinical and preclinical stage programs in the area of pain management, all of which utilize its bioerodible injectable and implantable delivery systems.

Recent Press Releases

01/06/12 - A.P. Pharma to Present at OneMedForum 2012 Financial Conference

11/07/11 - A.P. Pharma Announces Third Quarter 2011 Financial Results and Recent Corporate Progress

08/08/11 - A.P. Pharma Announces Second Quarter 2011 Financial Results and Reports on Recent Corporate Progress

More Releases >>